Will New Covid Treatments Be as Elusive for Poor Countries as Vaccines?
The New York Times
Merck has taken a step to make its antiviral pill available in poor nations, but many obstacles remain for broad access to coronavirus drugs.
Nearly a year after the first Covid-19 vaccination campaigns began, the vast majority of the shots have gone to people in wealthy nations, with no clear path toward resolving the disparity.
News this month that an antiviral medication had proved effective against the coronavirus in a large clinical trial has brought new hope of a turning point in the pandemic: a not-too-distant future when a simple pill could keep infected people from dying or falling severely ill.
The drug, molnupiravir, made by Merck, is easy to distribute and can be taken at home. The trial results showed it halved the risk of hospitalization and death among high-risk people early in their infections. The company has applied for emergency-use authorization from the Food and Drug Administration; a decision could come in early December.
The findings showed the highest mortality occurred among infants who were Black, lived in Southern states or had fetal birth defects.
As Lanzhou beef noodle soup goes from regional specialty to global attraction, I set out to find the best bowls in New York City.
As of Tuesday, 22 children and two adults had been infected, all of whom were unvaccinated, local officials said.
It’s the most energetic particle of its kind ever discovered, and scientists have no idea where it came from.
This 30-minute recipe for “Marry Me Salmon” feels special but is easy enough for a weeknight.
The internet erupted in controversy over Felisa Wolfe-Simon and colleagues’ claim of a microbe thriving on arsenic. Nearly 15 years later, she’s pursuing new research on the boundaries of life.
Once thought of as a byproduct of collard greens, brothy, complex potlikker takes on new life as a wonderful base for a Japanese staple.
The new research adds to the mysteries of the planet’s deepest interior region.
The billionaire is leading a group of investors in the unsolicited offer, which complicates the start-up’s plan to raise more money.
At cardiology conferences and diabetes meetings, doctors can’t help noticing that thin seems to be very in.
President Trump’s executive order is altering scientific exploration across a broad swath of fields, even beyond government agencies, researchers say.
After helping President Trump get elected, Elon Musk was poised to dominate the country’s A.I. policies. Then Mr. Altman sneaked into the White House.
Shock and grief rippled through the health community as lifelines for care were abruptly severed.